Experts has a new look! Let us know what you think of the updates.

Provide feedback
Home
Scholarly Works
Nintedanib, Pirfenidone and Pirfenidone Versus...
Preprint

Nintedanib, Pirfenidone and Pirfenidone Versus Nintedanib: A Systematic Review And Meta-Analysis

Abstract

Background: Patients with idiopathic pulmonary fibrosis have a poor overall prognosis. Only nintedanib and pirfenidone have been shown to reduce mortality.

Objective: This systematic review and meta-analysis aims to assess the efficacy of nintedanib, pirfenidone, and pirfenidone vs nintedanib on patient important outcomes.

Authors

Pitre T; Husnudinov R; Khalid MF; Zhang MC; Cui S; Tran J; Mah J; Helmeczi W; Su J; Jones A

DOI

10.21203/rs.3.rs-589439/v1

Preprint server

Research Square

Labels

Sustainable Development Goals (SDG)